Archive for Healthcare

Heathcare and Biotech Updates

Three COVID-19 Patients Treated with PLX Cells

By The Life Science Report

Source: Streetwise Reports   04/01/2020

Two programs, one new and the other ongoing, involving Pluristem Therapeutics’ regenerative products are reviewed in a Dawson James report.

In a March 30 research note, Dawson James Securities analyst Jason Kolbert reported that three high-risk COVID-19 patients were recently administered Pluristem Therapeutics Inc.’s (PSTI:NASDAQ) placental expanded (PLX) cells to evaluate the product as a potential treatment of the disease’s respiratory and inflammatory components.

“We are now seeing efforts from the leading regenerative medicine companies, including Pluristem, Mesoblast and Athersys, that these cell therapy treatments may help to soften the inflammatory cascade that initiates in acute respiratory distress syndrome (ARDS) patients and contributes to mortality,” Kolbert commented.

ARDS results from fluid collecting in the lungs’ alveoli, or air sacs, Kolbert explained. An infection in the lungs’ lobes can result from the coronavirus or pneumonia, “triggering an inflammatory cascade that causes death.”

Pluristem’s PLX cells, allogeneic, placenta derived and mesenchymal like, stimulate the body’s regenerative mechanisms, and thereby could possibly reduce COVID-19-induced pneumonia and pneumonitis, Kolbert wrote. “Previous preclinical findings of PLX cells revealed significant therapeutic effects in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal injury, which are potential complications of the severe COVID-19 infection,” he added.

The three COVID-19 patients who received Pluristem’s PLX cells have severe respiratory failure and are on ventilator support, noted Kolbert. The cells were dosed to them, in two hospitals in Israel, as part of a compassionate use program for the treatment of patients with the disease. This investigative program is a collaboration between Pluristem, the Berlin Institute of Health’s Center for Regenerative Therapy and the Charité Hospital’s Berlin Center for Advanced Therapies.

Kolbert also highlighted that the regenerative medicine firm has a late-stage clinical program in progress that Dawson James is watching, which is evaluating PLX cells in critical limb ischemia. Topline data from Pluristem’s Phase 3 trial in that indication could be available as early as next year.

Dawson James has a Buy rating and a $12 per share target price on Pluristem. The current share price is about $3.60.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures for Dawson James Securities, Pluristem Therapeutics, March 30, 2020,

The Firm does not make a market in the securities of the subject company(s). The Firm has NOT engaged in investment banking
relationships with PLURISTEM THERAPEUTICS in the prior twelve months, as a manager or co-manager of a public offering and has
NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in
the future from the subject company(s). The Firm has NOT received any other compensation from the subject company(s) in the last
12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of December 31, 2019, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm’s investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Analyst Certification: The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

( Companies Mentioned: PSTI:NASDAQ,
)

Kiniksa Shares Trade Up 30% on COVID-19 Pneumonia and Hyperinflammation Treatment

By The Life Science Report

Source: Streetwise Reports   03/31/2020

Shares of Kiniksa Pharmaceuticals traded higher after the company reported early success in treatment response for mavrilimumab in six patients with severe COVID-19 pneumonia and hyperinflammation.

This morning, Hamilton, Bermuda based biopharmaceutical company Kiniksa Pharmaceuticals Ltd. (KNSA:NASDAQ) announced “early evidence of treatment response with mavrilimumab, an investigational fully-human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα), in a treatment protocol in patients with severe coronavirus 2019 (COVID-19) pneumonia and hyperinflammation.”

The company advised that “the treatment protocol was conducted by Professor Lorenzo Dagna, MD, FACP, Head, Unit of Immunology, Rheumatology, Allergy and Rare Diseases IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University in Milan, Italy, within a COVID-19 Program directed by Professor Alberto Zangrillo, Head of Department of Anesthesia and Intensive Care of the Scientific Institute San Raffaele Hospital and Professor in Anesthesiology and Intensive Care, Università Vita-Salute San Raffaele.”

The firm stated that the treatment protocol tested the investigational drug mavrilimumab in an interventional, single-active-arm pilot experience. “Patients suffering from severe pulmonary involvement of COVID-19, acute respiratory distress, fever, and clinical and biological markers of systemic hyperinflammation status​ were treated with a single intravenous dose of mavrilimumab with the objective of reducing incidence of progression of acute respiratory failure, the need of mechanical ventilation, and the transfer to the intensive care unit.”

The company noted that so far six patients have been treated with mavrilimumab using the treatment protocol and that mavrilimumab has been well-tolerated. The firm reported that all of the patients showed an early resolution of fever and improvement in oxygenation within 1-3 days and none of the patients’ conditions progressed to require mechanical ventilation.

Professor Dagna commented, “Patients with COVID-19 die of a devastating pneumonia caused by a hyperinflammation syndrome…Last week my team administered mavrilimumab to 6 patients who were experiencing a steep decline of pulmonary status due to COVID-19 pneumonia. All patients responded on treatment, and 3 out of the 6 patients were discharged within 5 days. The data are compelling, and I look forward to continued studies of mavrilimumab in COVID-19.”

The company’s Chief Medical Officer John F. Paolini, MD, PhD, remarked, “These data are the first reported evidence of early treatment response with GM-CSF antagonism in COVID-19…By blocking GM-CSF signaling, mavrilimumab works upstream of interleukin-6 and potentially addresses the underlying pathophysiology of the hyperinflammation which may be responsible for the severe pneumonia of COVID-19. Controlled clinical studies are required to fully characterize the potential of mavrilimumab in this disease. Building upon our activities over the last several weeks, we continue to evaluate the data and next steps, including a potential Phase 2/3 clinical development program.”

The company explained that mavrilimumab has not yet been approved for any indication in any country and described mavrilimumab as “an investigational fully-human monoclonal antibody that is designed to antagonize GM-CSF signaling by binding to the alpha subunit of the GM-CSF receptor (GM-CSFRα).” The company listed that the lead indication for mavrilimumab is giant cell arteritis which is an inflammatory disease of medium-to-large arteries. The firm advised that mavrilimumab was safely dosed and met primary endpoints in Phase 2b clinical studies in Europe of more than 550 patients suffering from rheumatoid arthritis.

Kiniksa Pharmaceuticals is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating autoinflammatory and autoimmune diseases with significant unmet medical need. Kiniksa’s pipeline of product candidates across various stages of development include Rilonacept for the potential treatment of recurrent pericarditis; Mavrilimumab for the potential treatment of giant cell arteritis; KPL-716 for the potential treatment of a variety of pruritic diseases, including prurigo nodularis, a chronic inflammatory skin condition; and a few others.

Kiniksa Pharmaceuticals has a market capitalization of around $678.8 million with about 55.55 million outstanding shares. KNSA shares opened nearly 37% higher today at $16.74 (+$4.52, +36.99%) over the yesterday’s closing price of $12.22. The stock has traded today between $14.52 and $17.46 per share and currently is trading at $15.43 (+$3.21, +26.27%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: KNSA:NASDAQ,
)

Abbott Labs Launches Point-of-Care Diagnostic Tool that Can Detect COVID-19 in 5 Minutes

By The Life Science Report

Source: Streetwise Reports   03/30/2020

Shares of Abbott Laboratories opened 11% higher after the company reported that its ID NOW™ molecular point-of-care test to detect novel coronavirus will be available starting this week with plans to quickly ramp up production to deliver 50,000 tests per day.

Abbott Laboratories (ABT:NYSE) announced Friday that “the U.S. Food and Drug Administration has issued Emergency Use Authorization for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes.” The company advised that the test will run on its proprietary ID NOW™ platform and will be able to deliver very quick results in a complete range of healthcare provider locations including field emergency checkpoints, urgent care clinics, hospital emergency departments and doctors’ offices.

The firm noted that the ID NOW platform is small, lightweight and portable device that utilizes molecular technology to produce test results with high degrees of accuracy. The company indicated that the device is about the size of a toaster and only weighs about 6.6 pounds and added that its ID NOW platform is presently the most widely available molecular point-of-care testing platform in the U.S.

The company’s President and COO Robert B. Ford commented, “The COVID-19 pandemic will be fought on multiple fronts and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus…With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots.”

The firm advised that it is working with the government to deploy tests to areas where they can have the greatest impact and it will be making ID NOW COVID-19 tests available this week to U.S. healthcare providers in urgent care settings where the majority of ID NOW instruments are currently in use.

The firm described its ID NOW molecular platform, which it first introduced in 2014, as “the leading molecular point-of-care platform for Influenza A & B, Strep A and RSV testing in the U.S.” The company stated that “the ID NOW COVID-19 test comes a week after the company launched its Abbott m2000™ RealTime SARS-CoV-2 EUA test, which runs on the m2000™ RealTime System located in hospital and reference labs around the world.” The company indicated that together for both platforms combined it expects to manufacture around 5 million tests per month.

Abbott is headquartered in Abbott Park, Ill., and is a global healthcare provider of diagnostics, medical devices, consumer nutritionals and branded generic medicines. The company employs more than 107,000 people and distributes its products to more than 160 countries.

Abbott Labs has a market capitalization of around $131.5 billion with approximately 1.763 million shares outstanding. ABT shares opened 11% higher today at $82.83 (+$8.27, +11.09%) over Friday’s $74.56 closing price. The stock has traded today on more than three times average volume between $78.47 and $84.40 per share and is currently trading at $80.33 (+$5.77, +7.74%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: ABT:NYSE,
)

Eton Pharma Shares Climb 20% After Firm Secures US Rights for Pediatric Kidney Disease Drug

By The Life Science Report

Source: Streetwise Reports   03/27/2020

Shares of Eton Pharmaceuticals traded higher after the company reported that it has acquired U.S. marketing rights to pediatric orphan drug Alkindi® Sprinkle from Diurnal Group Plc.

Eton Pharmaceuticals Inc. (ETON:NASDAQ), which is focused on developing and commercializing injectable and pediatric oral liquid products, today announced that “it has acquired U.S. marketing rights to Alkindi® Sprinkle from Diurnal Group Plc (DNL:AIM).”

The company indicated that “Alkindi Sprinkle’s New Drug Application is currently under review with the U.S Food and Drug Administration (FDA) for approval as a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age and that the application has been assigned a Prescription Drug User Fee Act date of September 29, 2020.”

The company’s CEO Sean Brynjelsen commented, “Alkindi Sprinkle represents a transformational acquisition for Eton and a major step forward on our journey to become a leader in pediatric rare disease products. This product represents the largest market opportunity within our pipeline and adds a major near-term product launch…We are excited to be partnering with Diurnal to bring Alkindi Sprinkle to pediatric patients, and we plan to immediately begin launch activities to ensure its commercial success.”

Martin Whitaker, CEO of Diurnal Group Plc, remarked, “We have been impressed by Eton’s enthusiasm and vision for the product throughout the Alkindi Sprinkle partnering process…If approved, Alkindi Sprinkle will provide a major breakthrough in the U.S. as the only licensed treatment specifically designed for use in children with adrenal insufficiency, where there is a significant unmet patient need.”

The company stated that its leadership position in pediatric rare diseases products makes Alkindi Sprinkle a strong strategic fit with its current pediatric portfolio. The firm advised that it believes this product represents a $100 million market opportunity. The company estimates that approximately 5,000 pediatric patients suffer from adrenal insufficiency in the U.S. and noted that “current FDA-approved treatment options do not offer physicians the ability to properly dose and titrate for many of these pediatric patients.”

The company explained that Alkindi Sprinkle is a taste neutral sprinkle granule formulation of hydrocortisone and added that if approved it would be the first AI replacement therapy specifically designed and developed for children. The firm defined AI as a condition in which the adrenal glands do not produce adequate amounts of cortisol, which is often caused by Addison’s Disease or CAH. The firm reported that the FDA has granted Alkindi Sprinkle Orphan Drug Designation and the drug was approved in Europe in 2018 under the trade name Alkindi and has been launched in several countries there.

The license agreement terms included an immediate cash payment by Eton to Diurnal in the amount of $3.5 million. In addition, Eton issued Diurnal 379,474 shares of its common stock, representing approximately $1.5 million based on Eton’s average fifteen-day trailing stock price. The firm noted that “upon commercial launch of the product with Orphan Drug Exclusivity granted, Eton will pay Diurnal an additional cash milestone payment of $2.5 million.”

The company reported that “in conjunction with the Alkindi Sprinkle transaction, it has executed agreements to raise $7.8 million from the sale of 2.6 million shares of common stock at $3.00 per share and that the equity financing was led by Opaleye Management.” The company also stated that it amended its credit line to draw $2 million of debt financing with the option to draw an additional $3 million and that the proceeds will be used to support current and future licensing payments to Diurnal, as well as Alkindi Sprinkle-related commercial launch expenses.

Eton Pharmaceuticals is a specialty pharmaceutical company based in Deer Park, Ill., that focuses on acquiring, developing and commercializing high-value innovative products. The company mentioned that it is primarily focused on hospital injectable and pediatric oral liquid products. The company stated that its first commercial product Biorphen, which was launched in December 2019 is the only FDA approved ready-to-use formulation of phenylephrine injection. The firm indicated that it has eight other products in development including three that are currently under FDA review.

Diurnal Group is headquartered in the U.K. and is a specialty pharmaceutical company developing medicines for treatment of chronic endocrine conditions including CAH and AI.

Eton Pharmaceuticals began the day with a market capitalization of around $59.5 million with approximately 17.88 million shares outstanding. ETON shares opened 5% higher today at $3.51 (+$0.18, +5.41%) over yesterday’s $3.33 closing price. The stock has traded today between $3.44 and $4.87 per share and at present is trading at $4.07 (+$0.74, +22.22%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: ETON:NASDAQ,
)

Drone Firm Chosen to Integrate Breakthrough Health Diagnosis Technology in Fight Against Coronavirus

By The Life Science Report

Source: Streetwise Reports   03/26/2020

Draganfly and its partners aim to rapidly deploy the groundbreaking technology so it can help combat COVID-19.

In a news release, Draganfly Inc. (DFLY:CSE; DFLYF:OTCQB), which specializes in unmanned vehicle technology, announced it was chosen as the exclusive integration partner on a project aimed at combating COVID-19 and future health crises.

The Vital Intelligence Project combines a health and respiratory monitoring platform with new and existing camera networks and unmanned aerial vehicles (UAVs) and remotely piloted aircraft. The automated equipment monitors people’s health and vital signs, including temperature, heart rate and respiratory rate, and detects respiratory and infectious conditions.

The monitoring devices are ideal for use among crowds, workforces and at-risk groups, such as seniors, at care facilities for example, and high-traffic places, including airports, convention centers, cruise ships, border crossings and critical infrastructure facilities. Also, the data they collect can help in understanding certain health trends.

Draganfly’s role is to use its engineering, integration and distribution expertise and secure supply chain to commercialize and deploy the technology right away. Accordingly, the Canadian company signed a binding agreement, which affords an initial $1.5 million-plus budget.

The other partner in the project is Vital Intelligence Inc., a healthcare data services and deep learning company associated with the University of South Australia, which developed the technology with help from the Australian Department of Defense’s Defense Science and Technology Group.

“With fighting epidemics rising as a global priority, new versatile technologies, such as humanitarian mission UAVs, are immediately needed to detect and track outbreaks so that critical interventions can be deployed sooner and with greater effectiveness,” Dr. Jack Chow, adviser to the Vital Intelligence Project and the former first assistant director-general of the World Health Organization, said in the release.

“Draganfly has been selected because of its proven leadership in an industry so important to public safety at such a critical time. We look forward to working with global agencies and industry to rapidly deploy this important technology,” said Cameron Chell, CEO of Draganfly.

“Draganfly is honored to work on such an important project given the current pandemic facing the world with COVID-19. Health and respiratory monitoring will be vital for not only detection, but also utilizing the data to understand health trends. As we move forward, drones and autonomous technology doing detection will be an important part of ensuring public safety,” said Andy Card, Director of Draganfly and former Secretary of Transportation and White House Chief of Staff.

Draganfly

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Draganfly, a company mentioned in this article.

( Companies Mentioned: DFLY:CSE; DFLYF:OTCQB,
)

Coronavirus Propels Telemedicine into the Spotlight

McAlinden Research Partners takes a look at how telemedicine companies are positioned to profit both during and in the wake of the current pandemic, and offers a couple of options for investors.

By The Life Science Report – Source: McAlinden Research for Streetwise Reports   03/26/2020

Summary: Coronavirus could be the game changer that propels telemedicine into the mainstream. Virtual clinical services have been around since the ’90s but had failed to catch on. Now, a concerted effort by healthcare providers, insurance companies, the federal government and individuals to manage the COVID-19 pandemic has put telemedicine at the frontline of healthcare. Telemedicine companies have seen their usage volumes surge this year, along with their stock prices.

Telemedicine, a subset of telehealth, is hardly a new concept. Not only have virtual visits been around these past two decades, telemedicine is the most well-funded segment of digital health startups, having attracted billions of dollars to develop apps and websites that facilitate remote consultations with physicians. Telemedicine technology exists for follow-up visits, management of chronic conditions, medication management, specialist consultation and a host of other clinical services that can be provided remotely via secure video and audio connections.

At this point, most large health plans are on board with the notion. A 2019 Kaiser Family Foundation survey revealed that 82% of big U.S. employers include such a service in their biggest health plan, up from 27% in 2015. Yet, fewer than 10% of eligible employees have used a telemedicine service.

The biggest obstacles on the demand side have been the ingrained habit of people preferring in-person doctor visits, uncertainty about insurance reimbursement policies and lack of awareness by most people that they can connect with healthcare providers virtually.

There have been supply-side restrictions as well, one of them pertaining to physician licensing requirements. Most states, for example, will not allow physicians to practice across state lines, so a physician who wants to consult with patients residing in other states must be licensed to practice in those states.

While telemedicine has been slow to catch on so far, that’s about to change due to a concerted effort by the healthcare industry, government officials and individuals to stop the spread of the new coronavirus. As we noted in our EdTech report, black swan events can change the adoption rate of new technologies. The SARS crisis of 2003, for instance, contributed to the birth of China’s e-commerce industry, as quarantines and travel restrictions drove people to shop online. So too could the current pandemic mark a turning point for the telemedicine industry.

Health systems are deploying virtual services that can serve as their front line for coronavirus patients during the current crisis. The Centers for Disease Control & Prevention (CDC) has urged doctors and hospitals to conduct the initial triage of potentially infected patients remotely.

The CDC is also suggesting that patients with mild symptoms from COVID-19 be cared for at home when possible, but monitored closely using virtual check-ins. The goal is to avoid a run on the healthcare system. If the healthiest people don’t show up in emergency rooms, that could mean more resources are available to treat the sickest and most vulnerable patients.

Michigan-based Spectrum Health, which features 15 hospitals and 11 urgent care centers, began free telemedicine screenings for COVID-19 last week. The video-based visits determine whether a patient is at low risk or high risk of infection. Ideally, if a patient is deemed high risk, testing for the virus can be conducted at his/her home.

Members of Kaiser Permanente—the big, integrated healthcare provider and insurer based in California—are receiving care and instructions from their doctors via video, phone and text-style messaging. For these patients, telemedicine provides faster care and helps them avoid hospitals, where they risk either infecting others. Healthcare providers are also moving routine care (those unrelated to COVID-19) to virtual visits to free up capacity at hospitals and mitigate the risk of exposing patients to infection.

Telemedicine also received an additional boost under the $8.3 billion emergency funding measure from Congress, which eased restrictions on its use to treat people covered under the federal Medicare program. Until now, coverage of telemedicine had been limited primarily to residents of rural areas facing long road trips for treatment from specialists. The new bill, approved by Congress and signed by the president on March 6, extends that coverage to all 60 million Medicare enrollees.

Telemedicine companies in the U.S. are already benefitting from the disruption. Helped in part by a push from the federal government and health insurers, demand for their services have surged. Part of the increase is from people worried about COVID-19, but the surge was also driven by patients with other conditions seeking to avoid getting infected.

The volume of virtual visits has roughly doubled for artificial intelligence (AI)-enabled telehealth platform 98point6. Virtual clinic usage at Amwell (fka American Well) has surged roughly 40% above normal in recent days, and startup Ro said it has seen “significant” growth in coronavirus-related online visits. Shares of Teladoc Health Inc. (TDOC:NYSE), one of the rare publicly listed telemedicine companies, have skyrocketed since the start of the year.

If telemedicine establishes its worth during this period, that could accelerate the adoption of virtual health care nationally.

The same is true in other markets. Last year, China’s National Healthcare Security Administration (NHSA)—the agency that oversees state-backed health insurance plans—released new guidelines on pricing and insurance coverage for internet medical services. The move marked a significant milestone for telemedicine adoption in China, as it opened the way for local governments to provide reimbursement coverage for internet-based medical services.

How to Invest

The ETF that most closely captures this opportunity is the Robo Global Healthcare Technology and Innovation ETF (HTEC), which launched in June 2019. HTEC was a laggard last year, returning just +7% during the second half of 2019, while the SPY and U.S. Healthcare Providers ETF (IHF) posted respective returns of +10% and +17%. This year, HTEC’s performance is on par with SPY and a smidgeon better than IHF. With telemedicine catching on, HTECH could get a boost as well.

Investors seeking stock-specific exposure will quickly discover that most pureplay telemedicine companies are still private start-ups. There are two publicly listed companies: US-based Teladoc Health (TDOC) and China-based Ping An Healthcare and Technology Co. Ltd. (1833:HK). Year-to-date, Teladoc is up 42%, while Ping An is up 26%. Together, the two companies make up just 4.80% of HTEC’s portfolio, which is why they have had only a muted impact on the ETF’s performance.

This content was delivered to McAlinden Research Partners clients on March 16.
To receive all of MRP’s insights in your inbox Monday – Friday, follow this link for a free 30-day trial.

McAlinden Research Partners (MRP) provides independent investment strategy research to investors worldwide. The firm’s mission is to identify alpha-generating investment themes early in their unfolding and bring them to its clients’ attention. MRP’s research process reflects founder Joe McAlinden’s 50 years of experience on Wall Street. The methodologies he developed as chief investment officer of Morgan Stanley Investment Management, where he oversaw more than $400 billion in assets, provide the foundation for the strategy research MRP now brings to hedge funds, pension funds, sovereign wealth funds and other asset managers around the globe.

 

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) McAlinden Research Partners disclosures are below.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

McAlinden Research Partners:
This report has been prepared solely for informational purposes and is not an offer to buy/sell/endorse or a solicitation of an offer to buy/sell/endorse Interests or any other security or instrument or to participate in any trading or investment strategy. No representation or warranty (express or implied) is made or can be given with respect to the sequence, accuracy, completeness, or timeliness of the information in this Report. Unless otherwise noted, all information is sourced from public data.

McAlinden Research Partners is a division of Catalpa Capital Advisors, LLC (CCA), a Registered Investment Advisor. References to specific securities, asset classes and financial markets discussed herein are for illustrative purposes only and should not be interpreted as recommendations to purchase or sell such securities. CCA, MRP, employees and direct affiliates of the firm may or may not own any of the securities mentioned in the report at the time of publication.

( Companies Mentioned: TDOC:NYSE,
)

Coty Shares Rise 30% After Starting Production of Gel for Hand Sanitizer Use

By The Life Science Report

Source: Streetwise Reports   03/26/2020

Shares of Coty traded higher after the company reported that it has commenced production of hydro-alcoholic gel for use as hand sanitizer to help combat the COVID-19 virus.

Coty Inc. (COTY:NYSE) yesterday announced that “it has started producing hydro-alcoholic gel, which is used as hand sanitizer, to help combat the COVID-19 virus.” The company reported that production and donations are expected to reach tens of thousands of units per week.

The firm stated that the products will be distributed free of charge to medical and emergency services staff who are facing supply shortages due to the fast-spreading COVID-19 virus. The company also noted that it will be supplying the product to its employees who are working in its sanitizer producing plants for their own personal safety use and will also ship to pharmacy staff at some retail customer locations.

The firm advised that it has already produced the first batches of hand sanitizer at its factories in the U.S. and Monaco. The company stated that it expects that additional factories will begin production within a week subject to the amount of resources and materials available and local government guidelines and regulations.

The company’s CEO Pierre Laubies commented, “As a responsible beauty company, we make our resources and facilities available to help the communities we are operating in during these exceptionally challenging times…We are proud to support the brave professionals fighting on the frontlines against COVID-19 by providing hand sanitizer where it is needed.”

Coty’s COO Pierre-André Terisse added, “The health and safety of our employees is our top priority and we will take all possible measures and precautions to keep them healthy and safe as they work to protect our communities that we care for and serve…We are incredibly proud of our associates who are stepping up to contribute to the global fight against COVID-19.”

Coty is headquartered in New York, N.Y., and is one of the world’s largest beauty companies. The company owns a portfolio of many well-known brands in the beauty sector including fragrances, cosmetics, hair color, hair styling, and skin and body care. The company reports on its website that “it is the global leader in fragrance, a strong number two in professional hair color & styling, and number three in color cosmetics.” The firms products are sold worldwide over 150 countries.

Coty Inc. has a market capitalization of around $4.1 billion with approximately 760.6 million shares outstanding. COTY shares opened slightly higher today at $5.46 (+$0.08, +1.49%) over yesterday’s $5.38 closing price. The stock has traded today between $5.40 and $7.08 per share and is currently trading at $7.06 (+$1.68, +31.23%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: COTY:NYSE,
)

T2 Biosystems Shares Nearly Double on Worldwide COVID-19 Testing License Deal

By The Life Science Report

Source: Streetwise Reports   03/25/2020

Shares of T2 Biosystems Inc. traded 90% higher after the company reported that a new COVID-19 assay licensed from Hackensack Meridian Health’s Center for Discovery and Innovation will be adapted to run on its FDA-cleared T2Dx® Instrument.

Diagnostics company T2 BioSystems Inc. (TTOO:NASDAQ), which is focused on the rapid detection of sepsis-causing pathogens, yesterday announced that it has “entered into a worldwide licensing agreement for a rapid COVID-19, novel coronavirus test developed by the Center of Discovery and Innovation (CDI) at Hackensack Meridian Health (HMH), New Jersey’s largest and most comprehensive health network.”

The company stated that “the licensed coronavirus assay has been used by healthcare professionals within the HMH network, under the U.S. Food and Drug Administration’s Emergency Use Authorization guidance, to test and treat patients suspected of having coronavirus.”

The firm indicated that under terms of the agreement “it will adapt the coronavirus test to run on its T2Dx® Instrument, the same instrument used for the FDA-cleared T2Bacteria® and T2Candida® Panels.” In addition, it was noted that HMH will adopt the T2Dx® Instrument and test panels at the CDI.

The company’s President and CEO John Sperzel commented, “This agreement combines our FDA-cleared T2Dx platform with our joint scientific expertise to benefit patients at risk for both primary coronavirus infections, as well as associated secondary infections that may lead to sepsis…Data from prior flu pandemics indicated bacterial co-infection rates as high as 29%, and sepsis rates above 30% among patients admitted to hospital intensive care units. The ability to detect coronavirus and associated secondary bacterial or fungal infections that may lead to sepsis, without the need to wait days for a diagnostic result, allows clinicians to achieve targeted therapy faster, and can lead to reduced length of stay in the intensive care unit, freeing up beds for incoming patients.”

The firm stated that “by adding this complementary test to the T2Dx platform, capable of detecting SARS-CoV-2 (novel coronavirus), T2 Biosystems will be able to provide a comprehensive assessment of patients suspected of primary or secondary infections associated with coronavirus, when timely results are most critical.”

Robert C. Garrett, FACHE, CEO of Hackensack Meridian Health, remarked, “Our scientists at the Center for Discovery and Innovation have given our health network a crucial tool to treat patients in real-time…We are pleased to license the technology to T2 Biosystems and also adopt the T2Dx platform.”

Chief Scientific Officer and SVP of the CDI David S. Perlin, Ph.D., added, “We developed a highly sensitive and accurate coronavirus test that provides rapid, definitive results by combining the best elements found in the coronavirus tests developed by CDC and WHO…The T2Dx® Instrument is the perfect vehicle to expand our innovation to customers around worldwide.”

T2 Biosystems is based in Lexington, Mass., and is engaged in the rapid detection of sepsis-causing pathogens, biomarkers and other abnormalities. The firm is focused on improving patient care and reducing the medical care cost by helping clinicians effectively treat patients quicker than before. The company’s products which are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel and the T2ResistanceTM Panel.

HMH is a large non-profit health care group that offers a complete range of medical services, research and life-enhancing care. The organization has 17 hospitals, a behavioral health hospital and two rehabilitation hospitals.

The CDI is a member of HMH group, which aims to translate current innovations in science in order to improve clinical outcomes for patients with cancer, infectious diseases and other life-threatening and disabling conditions.

T2 Biosystems began the day with a market capitalization of around $39.3 million with approximately 100.8 million shares outstanding and a short interest of about 5.0%. TTOO shares opened more than 125% higher today at $0.893 (+$0.5032, +129.09%) over yesterday’s $0.3898 closing price. The stock has traded today between $0.6722 and $0.99 per share and is currently trading at $0.76 (+$0.38, +96.38%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: TTOO:NASDAQ,
)

Biopharma to Accelerate Alzheimer Trial Completion

By The Life Science Report

Source: Streetwise Reports   03/25/2020

The upcoming catalysts for Axsome Therapeutics and the effects of COVID-19 on its clinical activities are discussed in an H.C. Wainwright & Co. report.

In a March 20 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that Axsome Therapeutics Inc. (AXSM:NASDAQ) is speeding up completion of the ADVANCE-1 Phase 2/3 trial of AXS-05 in patients with Alzheimer’s disease agitation. Also, “Axsome shares remain undervalued and an even more attractive entry point may have presented itself due to the recent market downturn,” he added.

The biopharma’s current share price is about $62.52 per share. In comparison, H.C. Wainwright’s target price on the company is $200.

The purpose of Axsome Therapeutics accelerating completion of ADVANCE-1 is to keep the participants, a group at high risk from COVID-19, safe and ensure the study’s integrity. The U.S.-based firm decided to proceed in this manner following the just released Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic by the U.S. Food and Drug Administration. At this point, more than 90% of enrolled patients are estimated to have finished the study.

Consequently, the topline results for ADVANCE-1 are expected in early Q2/20, perhaps even in April, as opposed to Q3/20 previously.

Selvaraju noted that Axsome Therapeutics does not have any study enrollments or randomizations planned for the next several months. As such, it will not experience possible disruptions to its clinical program resulting from the coronavirus pandemic. The company may start one or more clinical trials much later in 2020 if and when the COVID-19 crisis may have abated.

Also, if the firm’s clinical activities this year end up being fewer than expected, this could translate to a lower cash burn, Selvaraju pointed out.

Data also are expected in the near term from the INTERCEPT study with AXS-07 and the STRIDE-1 trial with AXS-05. “The fact that ADVANCE-1 could generate data within only a few weeks of INTERCEPT and STRIDE-1 provides even greater incentive to own the stock,” commented Selvaraju.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from H.C. Wainwright & Co., Axsome Therapeutics Inc., Company Update, March 20, 2020

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Raghuram Selvaraju, Ph.D., certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst’s household has a financial interest in the securities of Axsome
Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of February 29, 2020 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Axsome Therapeutics, Inc..

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from Axsome Therapeutics, Inc. for non-investment banking services in the
previous 12 months.

The Firm or its affiliates did receive compensation from Axsome Therapeutics, Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Axsome Therapeutics, Inc. during the past 12 months.

The Firm does not make a market in Axsome Therapeutics, Inc. as of the date of this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

( Companies Mentioned: AXSM:NASDAQ,
)

Bellerophon Shares Take Off as FDA Grants Emergency Expanded Access for INOpulse for COVID-19 Treatment

By The Life Science Report

Source: Streetwise Reports   03/20/2020

Shares of Bellerophon Therapeutics reached a new 52-week high price after the firm reported that the FDA granted emergency expanded access for its INOpulse® nitric oxide delivery system device for use in treatment of COVID-19 virus.

Bellerophon Therapeutics Inc. (BLPH:NASDAQ), which focuses on developing innovative therapies in the treatment of cardiopulmonary diseases, today announced that “the U.S. Food and Drug Administration has granted emergency expanded access allowing its proprietary inhaled nitric oxide (iNO) delivery system, INOpulse®, to immediately be used for the treatment of COVID-19.”

The company explained that “nitric oxide (NO) is a naturally produced molecule that is critical to the immune response against pathogens and infections and that in vitro studies have shown that NO inhibits the replication of severe acute respiratory syndrome-related coronavirus (SARS-CoV) and improves survival for cells infected with SARS-CoV.”

The firm noted that “in a clinical study of patients infected with SARS-CoV, iNO demonstrated improvements in arterial oxygenation, a reduction in the need for ventilation support and an improvement in lung infiltrates observed on chest radiography.” The company stated that due to the genetic similarities between the two coronaviruses, the SARS-CoV data supports the potential for iNO to provide real benefit for patients infected with COVID-19.

The company reported that “the clinical spectrum of the COVID-19 infection ranges from mild signs of upper respiratory tract infection to severe pneumonia and death and added that preventing disease progression in patients with mild or moderate disease would improve morbidity/mortality and significantly reduce the impact on limited healthcare resources.”

The company’s CEO Fabian Tenenbaum commented, “Based on currently available data and its significant role in the immune response, we believe INOpulse has the potential to be a safe and effective treatment for COVID-19…INOpulse technology utilizes targeted pulsatile delivery of inhaled nitric oxide, providing important antiviral potential, as well as improved arterial oxygenation. Importantly, INOpulse is designed to treat patients in the outpatient setting, which may be critical in helping combat the further spread of the virus and significantly alleviate the mounting impact on hospitals and intensive care units. We look forward to supporting patients and physicians in order to help address the current COVID-19 global health pandemic.”

Bellerophon Therapeutics is a clinical-stage therapeutics company headquartered in Warren, N.J. The company concentrates on developing products that address medical needs in the treatment of cardiopulmonary diseases. The firm’s primary focus is on developing its nitric oxide therapy for patients with pulmonary hypertension using its INOpulse delivery system. The firm’s INOpulse device delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs which minimizes the amount of drug required for treatment.

Bellerophon Therapeutics began the day with a market capitalization of around $15.5 million with approximately 4.58 million shares outstanding and a short interest of about 2.1%. BLPH shares opened greatly higher today at $25.62 (+$22.23, +655.75%) over yesterday’s $3.39 closing price and reached a new 52-week high price this morning of $26.00. The stock has traded today between $15.28 and 26.00 per share and is currently trading at $18.67 (+$14.28, +443.39%).

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: BLPH:NASDAQ,
)